Caitong International Asset Management Co. Ltd Boosts Position in Koninklijke Philips N.V. (NYSE:PHG)

Caitong International Asset Management Co. Ltd boosted its holdings in shares of Koninklijke Philips N.V. (NYSE:PHG) by 1,170.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,439 shares of the technology company’s stock after buying an additional 2,247 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Koninklijke Philips were worth $62,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Choreo LLC raised its position in Koninklijke Philips by 4.6% during the 1st quarter. Choreo LLC now owns 14,530 shares of the technology company’s stock worth $369,000 after buying an additional 633 shares during the last quarter. Allworth Financial LP raised its position in Koninklijke Philips by 16.2% during the 1st quarter. Allworth Financial LP now owns 4,638 shares of the technology company’s stock worth $115,000 after buying an additional 645 shares during the last quarter. GeoWealth Management LLC grew its stake in shares of Koninklijke Philips by 4.5% during the 4th quarter. GeoWealth Management LLC now owns 19,255 shares of the technology company’s stock worth $488,000 after purchasing an additional 825 shares during the period. Assetmark Inc. grew its stake in shares of Koninklijke Philips by 1.7% during the 1st quarter. Assetmark Inc. now owns 59,806 shares of the technology company’s stock worth $1,519,000 after purchasing an additional 982 shares during the period. Finally, US Bancorp DE grew its stake in shares of Koninklijke Philips by 0.9% during the 1st quarter. US Bancorp DE now owns 109,831 shares of the technology company’s stock worth $2,790,000 after purchasing an additional 1,014 shares during the period. 13.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Koninklijke Philips Price Performance

Shares of NYSE PHG opened at $27.47 on Friday. The stock has a market capitalization of $26.45 billion, a price-to-earnings ratio of 144.58, a PEG ratio of 0.74 and a beta of 0.75. Koninklijke Philips N.V. has a 12 month low of $21.48 and a 12 month high of $32.91. The firm’s 50 day simple moving average is $24.79 and its 200-day simple moving average is $25.01. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.26 and a quick ratio of 0.81.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings data on Tuesday, July 29th. The technology company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.12. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $4.35 billion. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. Analysts expect that Koninklijke Philips N.V. will post 1.63 EPS for the current year.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.